Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 3050-3057

  Vergès, Bruno ^a,b   Guiu, Boris ^a   Cercueil, Jean Pierre ^a   Duvillard, Laurence ^b   Robin, Isabelle ^a   Buffier, Perrine ^a   Bouillet, Benjamin ^a   Aho, Serge ^a   Brindisi, Marie Claude ^a   Petit, Jean Michel ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

diabetes mellitus; kinetic; liver fat; retinol binding protein 4; triglycerides

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; RETINOL BINDING PROTEIN 4; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FAT CONTENT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAABDOMINAL FAT; LIVER FATTY DEGENERATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RISK ASSESSMENT; RISK FACTOR; SPECTROSCOPY; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEIN B-100; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RETINOL-BINDING PROTEINS, PLASMA; TRIGLYCERIDES;

EID: 84870057997     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.255190     Document Type: Article

References (44)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524. (Pubitemid 17050766)
2. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361-369. (Pubitemid 13078717)
3. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11year followup of the Paris Prospective Study. Diabetologia. 1989;32:300-304. (Pubitemid 19166483)
4. Ginsberg HN, Elam MB, Lovato LC, et al ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
5. Taskinen MR, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV. Effects of NIDDM on verylowdensity lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes. 1986;35:1268-1277. (Pubitemid 17186523)
6. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, YkiJärvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40:454-462. (Pubitemid 27132616)
7. Duvillard L, Pont F, Florentin E, GallandJos C, Gambert P, Vergès B. Metabolic abnormalities of apolipoprotein Bcontaining lipoproteins in noninsulindependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;30:685-694. (Pubitemid 30604069)
8. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356-362. (Pubitemid 41065039)
9. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinolbinding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354:2552-2563. (Pubitemid 43882351)
10. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein4 levels and clinical features of type 2 diabetes patients. J Clin Endo Metab. 2007:92:2712-2719. (Pubitemid 47037380)
11. von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, Bierhaus A, Dugi KA, Heemann U, Allolio B, Humpert PM. Retinolbinding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007;50:1930-1937. (Pubitemid 47222861)
12. Kotnik P, FischerPosovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol. 2011;165:703-711.
13. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinolbinding protein4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006:29:2457-2461. (Pubitemid 44912252)
14. Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Guardiola M, Heras M, Masana L. The APOA51131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis. 2010;20:243-248.
15. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X. Elevated retinolbinding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92:4827-4834. (Pubitemid 350223466)
16. Tan Y, Sun LQ, Kamal MA, Wang X, Seale JP, Qu X. Suppression of retinolbinding protein 4 with RNA oligonucleotide prevents highfat dietinduced metabolic syndrome and nonalcoholic fatty liver disease in mice. Biochim Biophys Acta. 2011;1811:1045-1053.
17. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU. High circulating retinolbinding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007;30:1173-1178. (Pubitemid 46684644)
18. Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Chen Y, Xiang K. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;79:185-190.
19. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006;29:1845-1850. (Pubitemid 44156640)
20. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-1144.
21. Chang YH, Lin KD, Wang CL, Hsieh MC, Hsiao PJ, Shin SJ. Elevated serum retinolbinding protein 4 concentrations are associated with renal dysfunction and uric acid in type 2 diabetic patients. Diabetes Metab Res Rev. 2008;24:629-634.
22. Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D, Hillon P, Krause D, Cercueil JP. Quantification of liver fat content: comparison of tripleecho chemical shift gradientecho imaging and in vivo proton MR spectroscopy. Radiology. 2009;250:95-102.
23. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metab Clin Exp. 1998;47:484-492. (Pubitemid 28180958)
24. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, Boston RC, Tada N, Mochizuki S, Defesche JC, Wilson JM, Rader DJ. Complete deficiency of the lowdensity lipoprotein receptor is associated with increased apolipoprotein B100 production. Arterioscler Thromb Vasc Biol. 2005;25:560-565. (Pubitemid 40315678)
25. Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, GrayMcGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17:1696-1701.
26. Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. HBPD INT. 2005;4:389-392.
27. Cengiz C, Ardicoglu Y, Bulut S, Boyacioglu S. Serum retinolbinding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis? Eur J Gastroenterol Hepatol. 2010;22:813-819.
28. Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Circulating and liver tissue levels of retinolbinding protein4 in nonalcoholic fatty liver disease. Hepatol Res. 2009;39:972-978.
29. Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M, Kahn BB. Serum retinolbinding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intraabdominal fat mass. Cell Metab. 2007;6:79-87. (Pubitemid 46995778)
30. Chen CC, Wu JY, Chang CT, Tsai FJ, Wang TY, Liu YM, Tsui HC, Chen RH, Chiou SC. Levels of retinolbinding protein 4 and uric acid in patients with type 2 diabetes mellitus. Metab Clin Exp. 2009;58:1812-1816.
31. Leite NC, Salles GF, Araujo AL, VillelaNogueira CA, Cardoso CR. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type2 diabetes mellitus. Liver Int. 2009;29:113-119.
32. Adiels M, Taskinen MR, Packard C, Caslake MJ, SoroPaavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, YkiJärvinen H, Borén J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765. (Pubitemid 43357551)
33. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol. 1997;8:146-153. (Pubitemid 27290460)
34. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis. 2010;211:353-360.
35. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructosefed hamster model. J Biol Chem. 2000;275:8416-8425. (Pubitemid 30180185)
36. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457-461. (Pubitemid 39372439)
37. Koh IU, Jun HS, Choi JS, Lim JH, Kim WH, Yoon JB, Song J. Fenretinide ameliorates insulin resistance and fatty liver in obese mice. Biol Pharm Bull. 2012;35:369-375.
38. Marill J, Idres N, Capron CC, Nguyen E, Chabot GG. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab. 2003;4:1-10. (Pubitemid 36131681)
39. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, Wiita P, Bok D, Sun H. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science. 2007;315:820-825.
40. Berry DC, Noy N. Signaling by vitamin A and retinolbinding protein in regulation of insulin responses and lipid homeostasis. Biochim Biophys Acta. 2012;1821:168-176.
41. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein Bcontaining lipoproteins in NIDDM. Diabetes. 1990;39:1017-1027. (Pubitemid 20263310)
42. Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naoumova R, Sönksen PH. Increased hepatic secretion of verylowdensity lipoprotein apolipoprotein B100 in obesity: a stable isotope study. Clin Sci. 1995;88:225-233.
43. Barrett PH, Chan DC, Watts GF. Thematic review series: patientoriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res. 2006;47:1607-1619. (Pubitemid 44222813)
44. Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and ApoB100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 1999;19:2714-2721. (Pubitemid 29536048)